It’s a moment of pride to announce that The ACME Laboratories Ltd. has stroke a historical Tripartite Collaborative Deal with CEMAG CARE, a privately-owned pharmaceutical company in France and CONCEPT FOUNDATION, an international non-governmental organization based in Geneva, Switzerland for development, manufacturing and commercialization of Quality Assured Misoprostol & Mifepristone Combipack (MMC) to be used for safe medical abortion globally. A team of 3 high officials from CEMAG CARE and 2 from CONCEPT FOUNDATION visited ACME’s facilities at Dhamrai on 16 March 2024 where the signing ceremony has taken place in presence of Mr. Mizanur Rahman Sinha, The Managing Director, Ms. Sabrina Juned and Mr. Fahim Sinha, The directors of The ACME Laboratories Ltd. The deal is a joint effort of ACME’s International Business Division and Technical Team at the facilities.
The collaboration defines that the CEMAG CARE having substantial experience and expertise, shall provide up-front investment & technical support to ACME for development of the product, generation of safety and efficacy data (Pharmacokinetic study), CONCEPT FOUNDATION shall arrange, support and coordinate the partnership for increasing access to quality assured MMC worldwide and ACME having requisite facilities & expertise shall develop, manufacture and commercialize the product globally jointly with CEMAG CARE.
The Agreement is expected to have a far-reaching impact that will take ACME to the next level in pharma arena as a Global Player.
The collaboration defines that the CEMAG CARE having substantial experience and expertise, shall provide up-front investment & technical support to ACME for development of the product, generation of safety and efficacy data (Pharmacokinetic study), CONCEPT FOUNDATION shall arrange, support and coordinate the partnership for increasing access to quality assured MMC worldwide and ACME having requisite facilities & expertise shall develop, manufacture and commercialize the product globally jointly with CEMAG CARE.
The Agreement is expected to have a far-reaching impact that will take ACME to the next level in pharma arena as a Global Player.